For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
38
references
 Top references
cited by
7
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      623
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Carnosic Acid Induces Apoptosis and Inhibits Akt/mTOR Signaling in Human Gastric Cancer Cell Lines

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gastric cancer is among the most common malignancies worldwide. Due to limited availability of therapeutic options, there is a constant need to find new therapies that could target advanced, recurrent, and metastatic gastric cancer. Carnosic acid is a naturally occurring polyphenolic abietane diterpene derived from Rosmarinus officinalis and reported to have numerous pharmacological effects. In this study, the cytotoxicity assay, Annexin V-FITC/PI, caspases 3, 8, and 9, cell cycle analysis, and Western blotting were used to assess the effect of carnosic acid on the growth and survival of human gastric cancer cell lines (AGS and MKN-45). Our findings showed that carnosic acid inhibited human gastric cancer cell proliferation and survival in a dose-dependent manner. Additionally, carnosic acid is found to inhibit the phosphorylation/activation of Akt and mTOR. Moreover, carnosic acid enhanced the cleavage of PARP and downregulated survivin expression, both being known markers of apoptosis. In conclusion, carnosic acid exhibits antitumor activity against human gastric cancer cells via modulating the Akt-mTOR signaling pathway that plays a crucial role in gastric cancer cell proliferation and survival.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: found

          Cancer Statistics, 2017.

          Rebecca Siegel, Kimberly D Miller, Ahmedin Jemal (2017)
          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States. For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher. However, sex disparities vary by cancer type. For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women. From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%). Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population. CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.
          Article 0 comments Cited 2088 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Burden of Gastric Cancer

            Aaron Thrift, Hashem El-Serag (2019)
            Gastric cancer is a global health problem, with more than 1 million people newly diagnosed with gastric cancer worldwide each year. Despite its worldwide decline in incidence and mortality over the past 5 decades, gastric cancer remains the third leading cause of cancer-related death. Knowledge of global as well as regional epidemiology and risk factors for gastric cancer is essential for the practicing gastroenterologist to make personalized decisions about risk stratification, screening, and prevention. In this article, we review the epidemiology of gastric cancer as well as screening and prevention efforts to reduce global morbidity and mortality from gastric cancer. First, we discuss the descriptive epidemiology of gastric cancer, including its incidence, mortality, survival, and secular trends. We combine a synthesis of published studies with an analysis of data from the International Agency for Research on Cancer GLOBOCAN project to describe the global burden of gastric cancer and data from the US Cancer Statistics registry to discuss the change in incidence of gastric cancer in the United States. Next, we summarize current knowledge of risk factors for gastric cancer. Finally, we discuss prevention strategies and screening efforts for gastric cancer.
            Article 0 comments Cited 499 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              mTOR signalling and cellular metabolism are mutual determinants in cancer

              Dirk Mossmann, Sujin Park, Michael N Hall (2018)
              Article 0 comments Cited 378 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Dejan Stojković: Role: Academic Editor
                Journal
                Journal ID (nlm-ta): Pharmaceuticals (Basel)
                Journal ID (iso-abbrev): Pharmaceuticals (Basel)
                Journal ID (publisher-id): pharmaceuticals
                Title: Pharmaceuticals
                Publisher: MDPI
                ISSN (Electronic): 1424-8247
                Publication date (Electronic): 08 March 2021
                Publication date Collection: March 2021
                Volume: 14
                Issue: 3
                Electronic Location Identifier: 230
                Affiliations
                [1 ]Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates; welhuneidi@ 123456sharjah.ac.ae (W.E.-H.); kbajbouj@ 123456sharjah.ac.ae (K.B.); jmuhammad@ 123456sharjah.ac.ae (J.S.M.); jtaneera@ 123456sharjah.ac.ae (J.T.)
                [2 ]Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates; arya.vinodnadat@ 123456gmail.com (A.V.); jsalam@ 123456sharjah.ac.ae (J.S.)
                [3 ]Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; gkhoder@ 123456sharjah.ac.ae
                [4 ]Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates; mohamed.saleh@ 123456sharjah.ac.ae
                [5 ]Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 33516, Egypt
                Author notes
                [* ]Correspondence: eabugharbieh@ 123456sharjah.ac.ae ; Tel.: +971-6505-7289
                Author information
                https://orcid.org/0000-0002-1580-2589
                https://orcid.org/0000-0001-7344-6095
                https://orcid.org/0000-0002-9565-1062
                https://orcid.org/0000-0002-6036-1022
                https://orcid.org/0000-0002-6405-6033
                https://orcid.org/0000-0002-3341-1063
                https://orcid.org/0000-0002-5972-0681
                Article
                Publisher ID: pharmaceuticals-14-00230
                DOI: 10.3390/ph14030230
                PMC ID: 7998299
                PubMed ID: 33800129
                SO-VID: 8665d468-ae36-4798-bfe6-2926e9638189
                Copyright © © 2021 by the authors.
                License:

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                Date received : 08 February 2021
                Date accepted : 03 March 2021
                Categories
                Subject: Article

                Keywords: carnosic acid,gastric cancer,apoptosis,akt,mtor,caspase,parp,survivin
                Data availability:
                Keywords: carnosic acid, gastric cancer, apoptosis, akt, mtor, caspase, parp, survivin

                Comments

                Comment on this article

                scite_

                Similar content623

                See all similar

                Cited by6

                See all cited by

                Most referenced authors1,276

                See all reference authors